Mary Ruisi
- Oncology top 5%
- Pulmonary and Respiratory Medicine top 10%
- Immunology top 10%
- Molecular Biology
- Surgery
- Co-authors
- Marcis BajarsDavid R. SpigelMustafa ÖzgüroğluJohan VansteenkisteHidenobu IshiiAndreas PolychronisMaciej KrzakowskiKeunchil Park
- Topics
- Cancer Immunotherapy and Biomarkers (16 papers)CAR-T cell therapy research (7 papers)Lung Cancer Treatments and Mutations (6 papers)
- Partner nations
- United StatesGermanyFrance
In The Last Decade
Mary Ruisi
28 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 81
- Oncology 787
- Pulmonary and Respiratory Medicine 332
- Immunology 246
- Molecular Biology 206
- Surgery 115
Countries citing papers authored by Mary Ruisi
This map shows the geographic impact of Mary Ruisi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Ruisi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Ruisi more than expected).
Fields of papers citing papers by Mary Ruisi
This network shows the impact of papers produced by Mary Ruisi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Ruisi. The network helps show where Mary Ruisi may publish in the future.
Co-authorship network of co-authors of Mary Ruisi
This figure shows the co-authorship network connecting the top 25 collaborators of Mary Ruisi. A scholar is included among the top collaborators of Mary Ruisi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Ruisi. Mary Ruisi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infectionbreakdown → | 120 |
| 4 | 5 | |
| 5 | 13 | |
| 6 | 1 | |
| 7 | 40 | |
| 8 | 5 | |
| 9 | 25 | |
| 10 | 3 | |
| 11 | 1 | |
| 12 | Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 studybreakdown → | 336 |
| 13 | 7 | |
| 14 | 1 | |
| 15 | 257 | |
| 16 | 1 | |
| 17 | 6 | |
| 18 | 47 | |
| 19 | 119 | |
| 20 | 1 |
About Mary Ruisi
Mary Ruisi is a scholar working on Oncology, Hematology and Internal Medicine, having authored 29 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (16 papers), CAR-T cell therapy research (7 papers) and Lung Cancer Treatments and Mutations (6 papers). The work is most often cited by research in Oncology (787 citations), Immunology (246 citations) and Pulmonary and Respiratory Medicine (332 citations). Mary Ruisi has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Marcis Bajars, David R. Spigel, Mustafa Özgüroğlu, Johan Vansteenkiste, Hidenobu Ishii, Andreas Polychronis, Maciej Krzakowski, Keunchil Park, Jong Seok Lee and Fabrice Barlési. Their work appears in journals such as JAMA, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.